. 2012 Nov 27;3(12):1588–1599. doi: 10.18632/oncotarget.733

Table 2. Effects of JQ1 on proliferation of primary leukemic cells.

				³H-thymidine-uptake
AML No#	FAB	WHO	Source PB/BM	+cytokines^** IC₅₀ (nM)	-cytokines IC₅₀ (nM)
1^*	M1	AML with t(9;11)	PB	280	n.t.
2	M5	AML monoblastic	BM	90	70
3	M5	AML with (9;11)/NPM1m	BM	160	240
4	M4	AML with mutated NPM1	PB	1,030	420
5	M1	AML with mutated NPM1	BM	420	n.t.
6	M4	AML myelomonocytic	BM	1,420	140
7	M1	AML with myelodysplasia	BM	40	n.t.
8^*	M5	AML with myelodysplasia	PB	40	40
9	M5	AML monoblastic	BM	50	50
10	M4	AML with inv16	BM	150	70
11	M2	AML with t(8;21)	BM	40	n.t.
12	M2	AML with t(8;21)	BM	60	n.t.
13	RAEB-T	AML with myelodysplasia	BM	n.t.	60
14	M1	AML without maturation	BM	n.t.	150
15^*	sec.	AML with myelodysplasia	PB	n.t.	1,800
16^*	M6a	acute erythroid leukemia	PB	40	n.t.
17^*	M4	AML myelomonocytic	BM	n.t.	280
19	M4	Therapy related AML	BM	n.t.	250
20	M1	AML with mutated NPM1	BM	n.t.	440
22^*	sec.	AML with myelodysplasia	BM	n.t.	70
23^*	sec.	AML with myelodysplasia	PB	n.t.	85
24^*	M4	AML myelomonocytic	BM	n.t.	230
25^*	sec.	AML with myelodysplasia	BM	n.t.	90
26	M4	AML with myelodysplasia	BM	n.t.	260
27^*	M4	AML monocytic	BM	n.t.	20
28	M1	AML with mutated NPM1	BM	n.t.	80
29	sec.	AML with myelodysplasia	BM	n.t.	30
30	M5	AML with mutated NPM1	BM	n.t.	110

These patients were analyzed at relapse or persistence of blasts.

^**

Cells were cultured in stem cell factor (SCF), interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF) (each 100 ng/ml).

Abbreviations: AML, acute myeloid leukemia; FAB, French-American-British cooperative study group; PB, peripheral blood; BM, bone marrow; n.t., not tested.